Symrise posts decade-high profitability as F&B division fuels growth
Key takeaways
- Symrise reported its highest profitability in a decade for FY 2025, with an adjusted EBITDA margin of 21.9% and record Business Free Cash Flow of €780 million (US$843 million).
- Organic growth of 2.8% was led by Food & Beverage and Fine Fragrances, though impairments on Swedencare and the Terpene business pulled reported EPS to €1.78 (US$1.92) against an adjusted €3.67 (US$3.96).
- Symrise launched an inaugural €400 million (US$432 million) share buyback and guided 2026 organic growth of 2–4%, below its own 5–7% medium-term CAGR target.
Symrise has reported its highest profitability in a decade for FY 2025, with an adjusted profit margin of 21.9% — up 120 basis points year-on-year — as organic sales growth of 2.8% and €50 million (US$54 million) in cost savings and efficiency gains, exceeding its €40 million (US$43 million) target, drove a record cash performance.
Reported revenues for the German flavor and fragrance specialist totaled €4.9 billion (US$5.3 billion), with adjusted earnings rising to €513 million (US$554 million) attributable to shareholders and adjusted earnings per share of €3.67 (US$3.96), up from €3.42 (US$3.69) in 2024.
Currency headwinds and portfolio changes reduced reported revenues by €210 million (US$227 million). Adjusted Business Free Cash Flow (BFCF) reached a record €780 million (US$843 million), representing a margin of 15.8%, up 220 basis points year-on-year, driven by earnings growth, reduced capital expansion intensity, and tighter working capital management.
“Last year (2025) was a year of disciplined execution guided by our purpose-driven One Symrise Strategy,” says Dr. Jean-Yves Parisot, CEO of Symrise. “Targeted efficiency measures, disciplined cost management, and continued investment in innovation and capacity expansion enabled Symrise to increase its adjusted EBITDA margin and significantly strengthen its cash conversion, providing a strong foundation for long-term value creation.”
Reported earnings weighed by impairments
The profitability picture is complicated by a series of one-time charges recorded in the fourth quarter. Non-cash impairments related to the Swedencare acquisition (€150 million/US$162 million) and the Terpene business (€148 million/US$160 million) — the latter of which Symrise is in the process of divesting, along with its Aqua Feed unit — pulled reported EBIT down to €465 million (US$502 million) from €718 million (US$776 million) in 2024. Reported earnings per share came in at €1.78 (US$1.92), against the adjusted figure of €3.67 (US$3.96).
Net debt, including pension and lease liabilities, totaled €2.1 billion (US$2.3 billion) at year-end, equating to 1.9x adjusted EBITDA and within the company’s updated long-term target range of 1.5x–2.5x. Excluding those obligations, net debt stood at €1.6 billion (US$1.7 billion), down €216 million (US$233 million) year-on-year.
Food & Beverage led Symrise’s 2.8% organic growth in 2025, helping the company reach decade-high profitability.
F&B and fine fragrances carry the growth
Within the Taste, Nutrition & Health segment — which generated revenues of €3 billion (US$3.2 billion) and an adjusted EBITDA margin of 23.8%, up 160 basis points — the Food & Beverage division was the standout performer, achieving mid-single-digit organic sales growth despite strong prior-year comparables.
EAME and North America both delivered high single-digit growth, while Beverages maintained momentum with high single-digit organic gains. Naturals and Savory delivered mid-single-digit organic sales growth, amid ongoing industry demand for reformulation that preserves sensory appeal.
Pet Food, however, was broadly flat for the year. The Pet Nutrition business unit cycled through strategic price actions taken at the start of 2025, with Pet Palatability achieving only low single-digit organic growth. Scent & Care posted organic growth of 3.2%, reaching revenues of €1.9 billion (US$2.1 billion), with an adjusted EBITDA margin of 18.9%, up 70 basis points.
Fine Fragrances delivered high single-digit organic growth, supported by new business wins in North America and Latin America, while Consumer Fragrances posted equally strong gains on the back of a solid business pipeline.
Cosmetic Ingredients recorded a low single-digit organic sales decline, attributed to high prior-year comparative figures for UV Filters, while the Micro Protection business unit achieved mid-single-digit growth. The Aroma Molecules division posted low single-digit organic growth, impacted by competition from Asia and what the company described as a dynamic market environment.
Capital returns and 2026 outlook
On January 12, Symrise announced an inaugural €400 million (US$432 million) share buyback, which commenced February 2 and will run through October 30, 2026. The Executive Board also proposed a 16th consecutive dividend increase to €1.25 (US$1.35) per share from €1.20 (US$1.30), subject to approval at the Annual General Meeting on May 6.
For 2026, Symrise expects organic sales growth of 2–4%, an adjusted EBITDA margin of 21.5–22.5%, and a BFCF margin above 14%. The company flagged that Q1 organic growth is expected to be down in the low single digits year-on-year, reflecting high comparatives from the prior period. Symrise reaffirmed its 2025–2028 medium-term targets, which call for an organic sales CAGR of 5–7%, an EBITDA margin of 21–23%, and a BFCF margin above 14%.
The company’s innovation agenda sits at the center of its Phase 2 One Symrise transformation, which it describes as pivoting toward commercial excellence and growth after two years of structural cost reduction.
Symrise recently published consumer research spanning Gen Alpha food preferences across Europe, Africa, and the Middle East, illustrating how its Symvision AI platform is being deployed to help F&B customers identify and validate new product concepts with emerging consumer segments.
